Novel perspectives on the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis
Canada 
Disclosure : Consultant/Advisor Axcan Pharma, Intercept Pharma.
[More]
[Less]
37 slide(s) – English – 2011-07-05
After viewing this presentation the participant will be able to:
- Describe immune-mediated causes of cholestasis
- Identify immunoregulatory loci associated with PBC
- Discuss the rationale for monoclonal antibody-based therapy in PBC
- Revisit the gut-liver connection in the pathogenesis of PSC
- Understand the role of PSC risk gene loci
New information has recently come to light on the pathogenesis of the autoimmune biliary diseases primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).
Genetic studies in particular have revealed insights into the pathogenesis of both diseases, and a basis for development of rational therapies. Although environmental triggers are also important they are less easily studied than genetic associations.
Dr. Hirschfield presents the latest information on pathogenesis and potential therapeutic strategies.
Copyright (c) 2011 MULTIWEBCAST.
|
